Skip to main content
Have a personal or library account? Click to login
Drug interactions with statins Cover

Drug interactions with statins

Acta Pharmaceutica
Volume 63 (2013): Issue 3 (September 2013)
By:  and    
Open Access
|Oct 2013
References

References

  1. 1. R. J. Herman, Drug interactions and the statins,(1999) 1281-1286.
    Search in Google Scholar
  2. 2, in:, 36th ed. (Ed. S. C. Sweetman), Pharmaceutical Press, London 2009, pp. 1155-1434.
    Search in Google Scholar
  3. 3. T. Uno, K. Sugimoto, K. Sugawara and T. Tateishi, The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazol,(2008) 276-281; DOI: 10.1097/FTD.0b013e31816e2d8e.
    Open DOISearch in Google Scholar
  4. 4. C. Bolego, R. Baetta, S. Bellosta, A. Corsini and R. Paoletti, Safety considerations for statins,(2002) 637-644.
    Open DOISearch in Google Scholar
  5. 5. H. M. Devold, E. Molden, S. Skurtveit and K. Furu, Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy,.(2009) 234-241; DOI: 10.1111/j.1365-2125.2008.03345.x.
    Open DOISearch in Google Scholar
  6. 6. E. Molden, K. S. Andersson and D. Jacobsen, Interactions between statins and macrolide antibiotics,(2007) 1660-1661.
    Search in Google Scholar
  7. 7. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paolett and F. Bernini, New insights into the pharmacodynamic and pharmacokinetic properties of statins,(1999) 413-428.
    Open DOISearch in Google Scholar
  8. 8. C. M. White, A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin,(2002) 963-970.
    Open DOISearch in Google Scholar
  9. 9. R. Bhindi, O. Ormerod, J. Newton, A. P. Banning and L. Tesla, Interaction between statins and clopidogrel: is there anything clinically relevant?(2008) 915-925; DOI: 10.1093/qjmed/ hcn089.
    Search in Google Scholar
  10. 10. P. J. Neuvonen, M. Niemi and J. T. Backman, Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance,(2006) 565-581.
    Open DOISearch in Google Scholar
  11. 11. K. M. Giacomini, S. M. Huang, D. J. Tweedie, L. Z. Benet, K. L. Brouwer, X. Chu, A. Dahlin, R. Evers, V. Fischer, K. M. Hillgren, K. A. Hoffmaster, T. Ishikawa, D. Keppler, R. B. Kim, C. A. Lee, M. Niemi, J. W. Polli, Y. Sugiyama, P. W. Swaan, J. A. Ware, S. H. Wright, S. W. Yee, M. J. Zamek-Gliszczynski and L. Zhang, Membrane transporters in drug development,.(2010) 215-236; DOI: 10.1038/nrd3028.
    Open DOISearch in Google Scholar
  12. 12. M. Karlgren, G. Ahlin, C. A. Bergström, R. Svensson, J. Palm and P. Artursson, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions,(2012) 411-426; DOI: 10.1007/s11095-011-0564-9.
    Open DOISearch in Google Scholar
  13. 13. E. Link, S. Parish, J. Armitage, L. Bowman, S. Heath, F. Matsuda, I. Gut, M. Lathrop and R. Collins, SLCO1B1 variants and statin-induced myopathy - a genomewide study,(2008) 789-799; DOI: 10.1056/NEJMoa0801936.
    Open DOISearch in Google Scholar
  14. 14. D. Voora, S. H. Shah, I. Spasojevic, S. Ali, C. R. Reed, B. A. Salisbury and G. S. Ginsburg, The SLCO1B1*5 genetic variant is associated with statin-induced side effects,(2009) 1609-1616; DOI: 10.1016/j.jacc.2009.04.053.
    Open DOISearch in Google Scholar
  15. 15. J. P. F. Bai, Ongoing challenges in drug interaction safety: from exposure to pharmacogenomics,(2010) 62-71.
    Open DOISearch in Google Scholar
  16. 16. J. Mwinyi, A. Johne, S. Bauer, I. Roots and T. Gerloff, Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetic,(2004) 415-421.
    Open DOISearch in Google Scholar
  17. 17. M. Niemi, E. Schaeffeler, T. Lang, M. F. Fromm, M. Neuvonen, C. Kyrklund, J. T. Backman, R. Kerb, M. Schwab, P. J. Neuvonen, M. Eichelbaum and K. T. Kivistö, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1),(2004) 429-440.
    Open DOISearch in Google Scholar
  18. 18. Y. Shitara, Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions,.(2011) 220-227; DOI: 10.2133/dmpk.DMPK-10-RV-094.
    Open DOISearch in Google Scholar
  19. 19. K. Morimoto, T. Oishi, S. Ueda, M. Ueda, M. Hosokawa and K. Chib, A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy,.(2004) 453-455.
    Open DOISearch in Google Scholar
  20. 20. Y. Y. Lau, H. Okochi, Y. Huang and L. Z. Benet, Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems,(2006) 762-771.
    Open DOISearch in Google Scholar
  21. 21. G. A. Schmidt, J. D. Hoehns, J. L. Purcell, R. L. Friedman and Y. Elhawi, Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir,(2007) 411-416.
    Open DOISearch in Google Scholar
  22. 22. V. Borders-Hemphill, Concurrent use of statins and amiodarone,(2009) 372-379.
    Open DOISearch in Google Scholar
  23. 23. S. Lam, N. Partovi, L. S. Ting, and M. H. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?,(2008) 1037-1047; DOI: 10.1345/aph.1K628.
    Open DOISearch in Google Scholar
  24. 24. D. Williams and J. Freely, Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors,(2002) 343-370.
    Open DOISearch in Google Scholar
  25. 25. S. Bellosta, R. Paoletti and A. Corsini, Safety of statins: focus on clinical pharmacokinetics and drug interactions,(2004) III50-III57; DOI: 10.1161/01.CIR.0000131519.15067.1f.
    Open DOISearch in Google Scholar
  26. 26. K. Ohyama, M. Nakajima, M. Suzuki, N. Shimada, H. Yamazaki and T. Yokoi, Inhibitory effects of amiodarone and its N-desethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions,(2000) 244-253.
    Search in Google Scholar
  27. 27. U. M. Chouhan, S. Chakrabarti and L. J. Millward, Simvastatin interaction with clarithromycin and amiodarone causing myositis,(2005) 1760-1761.
    Open DOISearch in Google Scholar
  28. 28. A. Marot, J. Morelle, V. A. Chouinard, M. Jadoul, M. Lambert and N. Demoulin, Concomitant use of simvastatin and amiodarone resulting in severe rhabdomyolysis: a case report and review of the literature,(2011) 134-136.
    Search in Google Scholar
  29. 29. B. Ricaurte, A. Guirguis, H. C. Taylor and D. Zabriskie, Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity,(2006) 753-757.
    Open DOISearch in Google Scholar
  30. 30. A. Alsheikh-Ali and R. Karas, Adverse events with concomitant amiodarone and statin therapy,(2005) 95-97.
    Open DOISearch in Google Scholar
  31. 31. S. Karimi, A. Hough, C. Beckey and D. Parra, Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center,(2010) 472-481.
    Open DOISearch in Google Scholar
  32. 32. DRUGDEX/MICROMEDEX. Statins. Healthcare Series for Windows. Micromedex Thomson Healthcare. 2012. Retrieved from:http://www.thomsonhc.com/home/dispatch (accessed July 6, 2012).
    Search in Google Scholar
  33. 33. G. W. Amsden, O. Kuye and G. C. Wei, A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers,(2002) 444-449.
    Open DOISearch in Google Scholar
  34. 34. G. W. Amsden, Macrolides versus azalides: a drug interaction update,(1995) 906-917.
    Open DOISearch in Google Scholar
  35. 35. M. P. Pai, D. M. Graci and G. W. Amsden, Macrolide drug interactions: an update,(2000) 495-513.
    Open DOISearch in Google Scholar
  36. 36. J. W. Grunden and K. A. Fisher, Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin,(1997) 859-863.
    Open DOISearch in Google Scholar
  37. 37. M. Z. Skrabal, J. A. Stading, C. A. Cannella and M. S. Monaghan, Two cases of rhabdomyolysis associated with high-dose simvastatin,(2003) 578-581.
    Open DOISearch in Google Scholar
  38. 38. J. Strandell, A. Bate, S. Hägg and I. R. Edwards, Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction,(2009) 427-434; DOI: 10.1111/j. 1365-2125.2009.03473.x.
    Search in Google Scholar
  39. 39. R. B. Kim, C. Wandel, B. Leake, M. Cvetkovic, M. F. Fromm, P. J. Dempsey, M. M. Roden, F. Belas, A. K. Chaudhary, D. M. Roden, A. J. Wood and G. R. Wilkinson, Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein,(1999) 408-414.
    Open DOISearch in Google Scholar
  40. 40. C. Marzolini, E. Paus, T. Buclin and R. B. Kim, Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance,(2004) 13-33.
    Open DOISearch in Google Scholar
  41. 41. S. Eberl, I. Bachmakov, F. Dörje and M. F. Fromm, The effect of macrolide antibiotics on the function of the drug transporter P-glycoprotein,(2005) R145.
    Open DOISearch in Google Scholar
  42. 42. J. Rengelshausen, C. Goggelmann, J. Burhenne, K. D. Riedel, J. Ludwig, J. Weiss, G. Mikus, I. Walter-Sack and W. Haefeli, Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction,.(2003) 32-38.
    Open DOISearch in Google Scholar
  43. 43. T. Jacobson, Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors,(2004) 1140-1146.
    Open DOISearch in Google Scholar
  44. 44. A. Seithel, S. Eberl, K. Singer, D. Auge, G. Heinkele, N. B. Wolf, F. Dörje, M. F. Fromm and J. König, The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3,(2007) 779-786.
    Open DOISearch in Google Scholar
  45. 45. M. Hirano, K. Maeda, Y. Shitara and Y. Sugiyama, Drug-drug interaction between pitavastatin and various drugs via OATP1B1,(2006) 1229-1236.
    Open DOISearch in Google Scholar
  46. 46. R. D. Sawant, Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin,.(2009) 78-79.
    Search in Google Scholar
  47. 47. M. Ishigami, M. Uchiyama, T. Kondo, H. Iwabuchi, S. Inoue, W. Takasaki, T. Ikeda, T. Komai, K. Ito and Y. Sugiyama, Inhibition of in vitro metabolism of simvastatin by itraconazole in humans and prediction of in vivo drug-drug interactions,(2001) 622-631.
    Open DOISearch in Google Scholar
  48. 48. K. T. Kivistö, T. Kantola and P. J. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin,(1998) 49-53.
    Open DOISearch in Google Scholar
  49. 49. K. Akram, S. Rao and M. Parker, A lesson for everyone in drug-drug interactions (letter),(2007) 19-20.
    Open DOISearch in Google Scholar
  50. 50. R. Gilad and Y. Lampl, Rhabdomyolysis induced by simvastatin and ketoconazole treatment,(1999) 295-297.
    Search in Google Scholar
  51. 51. H. Itakura, D. Vaughn, D. Haller and P. O’Dwyer, Rhabdomyolysis from cytochrome P-450 interaction of ketoconazole and simvastatin in prostate cancer,(2003) 613; DOI: 10. 1016/S0022-5347(05)63967-5.
    Search in Google Scholar
  52. 52. C. Stein, S. Goel and R. Ghavamian, Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy,(2007) 277-278.
    Open DOISearch in Google Scholar
  53. 53. O. Findling, N. Meier, J. Sellner, K. Nedeltchev and M. Arnold, Clinical reasoning: rhabdomyolysis after combined treatment with simvastatin and fluconazole,(2008) 34-37; DOI: 10.1212/01.wnl.0000327566.57661.09.
    Open DOISearch in Google Scholar
  54. 54. C. C. Franz, M. Bruggisser, S. Krähenbühl and A. E. Rätz Bravo, Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole,(2011) 273-284; DOI: 10.1024/1661-8157/a000491.
    Open DOISearch in Google Scholar
  55. 55. R. Hazin, J. Y. Abuzetun, M. Suker and J. Porter, Rhabdomyolysis induced by simvastatin-fluconazole combination,(2008) 444-446.
    Open DOISearch in Google Scholar
  56. 56. A. Shaukat, M. Benekli, G. D. Vladutiu, J. L. Slack, M. Wetzler and M. R. Baer, Simvastatin-fluconazole causing rhabdomyolysis,(2003) 1032-1035.
    Open DOISearch in Google Scholar
  57. 57. N. E. Azie, D. C. Brater, P. A. Becker, D. R. Jones and S. D. Hall, The interaction of diltiazem with lovastatin and pravastatin,(1998) 369-377.
    Open DOISearch in Google Scholar
  58. 58. O. Mousa, D. C. Brater, K. J. Sunblad and S. D. Hall, The interaction of diltiazem with simvastatin,(2000) 267-274.
    Open DOISearch in Google Scholar
  59. 59. Y. Sugiyama, N. Mimura, T. Kuwabara, H. Kobayashi, J. Ushiki and E. Fuse, Effect of benidipine on simvastatin metabolism in human liver microsomes,(2007) 199-205.
    Open DOISearch in Google Scholar
  60. 60. J. J. Lewin, J. M. Nappi and M. H. Taylor, Rhabdomyolysis with concurrent atorvastatin and diltiazem,(2002) 1546-1549.
    Open DOISearch in Google Scholar
  61. 61. R. Peces and A. Pobes, Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem,(2001) 117-118.
    Open DOISearch in Google Scholar
  62. 62. T. Prueksaritanont, B. Ma, C. Tang, Y. Meng, C. Assang, P. Lu, P. J. Reider, J. H. Lin and T. A. Baillie, Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations,(1999) 291-298.
    Search in Google Scholar
  63. 63. M. Jasiñska, J. Owczarek and D. Orszulak-Michalak, The influence of simvastatin at high dose and diltiazem on myocardium in rabbits, the biochemical study,(2006) 386-390.
    Search in Google Scholar
  64. 64. T. Kantola, K. T. Kivisto and P. J. Neuvonen, Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations,(1998) 177-182.
    Open DOISearch in Google Scholar
  65. 65. H. Satoh, F. Yamashita, M. Tsujimoto, H. Murakami, N. Koyabu, H. Ohtani and Y. Sawada, Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B,(2005) 518-523.
    Open DOISearch in Google Scholar
  66. 66. P. Li, P. S. Callery, L. S. Gan and S. K. Balani, Estearase inhibition by grapefruit juice flavonoids leading to a new drug interaction,.(2007) 1203-1208.
    Open DOISearch in Google Scholar
  67. 67. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin,.(1999) 118-127.
    Open DOISearch in Google Scholar
  68. 68. J. J. Lilja, K. T. Kivistö and P. J. Neuvonen, Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors,.(1998) 477-483.
    Search in Google Scholar
  69. 69. J. J. Lilja, M. Neuvonen and P. J. Neuvonen, Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin,.(2004) 56-60.
    Open DOISearch in Google Scholar
  70. 70. I. Fukazawa, N. Uchida, E. Uchida and H. Yasuhara, Effects of grapefruit on pharmacokinetics of atorvastatin and pravastatin in Japanese,.(2003) 448-455.
    Open DOISearch in Google Scholar
  71. 71. H. Ando, S. Tsuruoka, H. Yanagihara, K. Sugimoto, M. Miyata, Y. Yamazoe, T. Takamura, S. Kaneko and A. Fujimura, Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin,(2005) 494-497.
    Open DOISearch in Google Scholar
  72. 72. Y. Koitabashi, T. Kumai, N. Matsumoto and M. Watanabe, Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects,.(2006) 2852-2859.
    Open DOISearch in Google Scholar
  73. 73. A. V. Sorokin, B. Duncan, R. Panetta and P. D. Thompson, Rhabdomyolysis associated with pomegranate juice consumption,(2006) 705-706.
    Open DOISearch in Google Scholar
  74. 74. T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima and Saito Y. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine,(2003) 381-389.
    Search in Google Scholar
  75. 75. Y. Shitara, T. Itoh, H. Sato, A. P. Li and Y. Sugiyam, Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A,(2003) 610-616.
    Open DOISearch in Google Scholar
  76. 76. S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass and D. W. Schneck, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine,(2004) 167-177.
    Open DOISearch in Google Scholar
  77. 77. J. Tong, G. Laport and R. Lowsky, Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma,(2005) 739-740.
    Open DOISearch in Google Scholar
  78. 78. A. Lasocki, B. Vote, R. Fassett and E. Zamir, Simvastatin-induced rhabdomyolysis following cyclosporine treatment for uveitis,.(2007) 345-346.
    Open DOISearch in Google Scholar
  79. 79. S. Vives, M. Batlle, E. Montané and J. M. Ribera, Rhabdomyolysis and renal failure secondary to interaction between simvastatin, ciclosporin A and risperidone in an allogeneic stem cell transplantation patient,(2008) 676.
    Search in Google Scholar
  80. 80. J. W. Park, R. Siekmeier, M. Merz, B. Krell, S. Harder, W. März, D. Seidel, S. Schüler and W. Gross, Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A,(2002) 439-450.
    Open DOISearch in Google Scholar
  81. 81. M. Veeraputhiran and M. Sundermeyer, Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin,(2008) 232-234; DOI: 10.3816/CLC. 2008.n.036.
    Search in Google Scholar
  82. 82. P. F. Katsakiori, E. P. Papapetrou, D. S. Goumenos, G. C. Nikiforidis and C. S. Flordellis, Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients,(2011) 385-388; DOI: 10.4103/0253-7613.83106.
    Open DOISearch in Google Scholar
  83. 83. R. H. Jacobson, P. Wang and C. J. Glueck, Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone,(1997) 296-297.
    Open DOISearch in Google Scholar
  84. 84. N. S. Karnik and J. R. Maldonado, Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminiti,(2005) 565-568.
    Search in Google Scholar
  85. 85. Serzone (nefazodone hydrochloride) US prescribing information, Bristol-Myers Squibb Company, January 2005.
    Search in Google Scholar
  86. 86. C. B. Hare, M. P. Vu, C. Grunfeld and H. W. Lampiris, Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death,(2002) 111-112.
    Open DOISearch in Google Scholar
  87. 87. P. E. Sax, Strategies for management and treatment of dyslipidemia in HIV/AIDS,(2006) 149-157.
    Open DOISearch in Google Scholar
  88. 88. P. H. Hsyu, M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis and B. M. Kerr, Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin,.(2001) 3445-3450.
    Open DOISearch in Google Scholar
  89. 89. R. A. Carr, A. K. Andre, R. J. Bertz, W. Lam, M. Chang, P. Chen, P. Williams, B. Bernstein and E. Sun, Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin, 40th ICAAC, Toronto, September 2000, presentation 1644.
    Search in Google Scholar
  90. 90. C. J. Fichtenbaum, J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, F. Aweeka and NIAID AIDS Clinical Trials Group, Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047,(2002) 569-577.
    Open DOISearch in Google Scholar
  91. 91. J. A. Aberg, S. L. Rosenkranz, C. J. Fichtenbaum, B. L. Alston, S. W. Brobst, Y. Segal, J. G. Gerber and ACTG A5108 team, Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108,(2006) 725-729.
    Open DOISearch in Google Scholar
  92. 92. P. A. Pham, C. J. la Porte L. S., Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner and D. W. Cameron, Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers,(2009) 4385-4392; DOI: 10.1128/AAC.00449-09.
    Open DOISearch in Google Scholar
  93. 93. R. Stern, R. Abel, G. L. Gibson and J. Besserer, Atorvastatin does not alter the anticoagulant activity of warfarin,(1997) 1062-1064.
    Open DOISearch in Google Scholar
  94. 94. H. Hickmott, H. Wynne and F. Kamali, The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements,.(2003) 949-950.
    Open DOISearch in Google Scholar
  95. 95. J. C. Lin, M. K. Ito, S. N. Stolley, A. P. Morreale and D. B. Marcus, The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin,(1999) 86-90.
    Open DOISearch in Google Scholar
  96. 96. E. A. Sconce, T. I. Khan, A. K. Daly, H. A. Wynne and F. Kamali, The impact of simvastatin on warfarin disposition and dose requirements,.(2006) 1422-1424.
    Open DOISearch in Google Scholar
  97. 97. T. Westergren, P. Johansson and E. Molden, Probable warfarin-simvastatin interaction,(2007) 1292-1295.
    Open DOISearch in Google Scholar
  98. 98. S. Ahmad, Lovastatin warfarin interaction,(1990) 2407.
    Open DOISearch in Google Scholar
  99. 99. H. S. Hoffman, The interaction of lovastatin and warfarin,(1992) 107.
    Search in Google Scholar
  100. 100. E. A. Iliadis and M. F. Konwinski, Lovastatin during warfarin therapy resulting in bleeding,(1995) 31.
    Search in Google Scholar
  101. 101. S. S. Kline and C. C. Harrell, Potential warfarin-fluvastatin interaction,(1997) 790.
    Search in Google Scholar
  102. 102. L. E. Trilli, C. L. Kelley, S. L. Aspinall and B. A. Kroner, Potential interaction between warfarin and fluvastatin,(1996) 1399-1402.
    Open DOISearch in Google Scholar
  103. 103. M. J. Murphy and M. H. Dominiczak, Efficacy of statin therapy: possible effect of phenytoin,(1999) 359-360.
    Open DOISearch in Google Scholar
  104. 104. K. M. Tan, J. G. Kelly and K. McGarry, Statins and phenytoin interact - a case history,(2008) 147-148.
    Open DOISearch in Google Scholar
  105. 105. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations,(2000) 592-597.
    Open DOISearch in Google Scholar
  106. 106. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects,(2004) 181-187.
    Open DOISearch in Google Scholar
  107. 107. R. Eggertsen, A. Andreasson and L. Andrén, Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin,(2007).
    Open DOISearch in Google Scholar
  108. 108. K. Sugimoto, M. Ohmori, S. Tsuruoka, K. Nishiki, A. Kawaguchi, K. Harada, M. Arakawa, K.\ Sakamoto, M. Masada, I. Miyamori and A. Fujimura, Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin,(2001) 518-524.
    Open DOISearch in Google Scholar
  109. 109. W. C. Lau, L. A. Waskell, P. B. Watkins, C. J. Neer, K. Horowitz, A. S. Hopp, A. R. Tait, D. G. Carville, K. E. Guyer and E. R. Bates, Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction,(2003) 32-37.
    Search in Google Scholar
  110. 110. A. Blagojevic, J. A. Delaney, L. E. Lévesque, N. Dendukuri, J. F. Boivin and J. M. Brophy, Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study,(2009) 362-369; DOI: 10.1002/pds.1716.
    Open DOISearch in Google Scholar
  111. 111. O. Gorchakova, N. von Beckerath, M. Gawaz, A. Mocz, A. Joost, A. Schömig and A. Kastrati, Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting,(2004) 1898-1902.
    Open DOISearch in Google Scholar
  112. 112. J. V. Mitsios, A. I. Papathanasiou, F. I. Rodis, M. Elisaf, J. A. Goudevenos and A. D. Tselepis, Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes,(2004) 1335-1338.
    Open DOISearch in Google Scholar
  113. 113. I. Muller, F. Besta, C. Schulz, Z. Li, S. Massberg and M. Gawaz, Effects of statins on platelet inhibition by a high loading dose of clopidogrel,(2003) 2195-2197.
    Open DOISearch in Google Scholar
  114. 114. J. Saw, D. M. Brennan, S. R. Steinhubl, D. L. Bhatt, K. H. Mak, K. Fox and E. J. Topol, Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial,(2007) 291-295.
    Open DOISearch in Google Scholar
  115. 115. V. L. Serebruany, M. G. Midei, A. I. Malinin, B. R. Oshrine, D. R. Lowry, D. C. Sane, J. F. Tanguay, S. R. Steinhubl, P. B. Berger, C. M. O’Connor and C. H. Hennekens, Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study,(2004) 2051-2057.
    Search in Google Scholar
  116. 116. P. Vinholt, T. S. Poulsen, L. Korsholm, S. R. Kristensen, J. Hallas, P. Damkier and H. Mickley, The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease,(2005) 438-443.
    Search in Google Scholar
  117. 117. A. Zahno, K. Brecht, M. Bodmer, D. Bur, D. A. Tsakiris and S. Krähenbühl, Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro,(2010) 393-404; DOI: 10.1111/j.1476-5381.2010.00881.x.
    Open DOISearch in Google Scholar
  118. 118. L. R. Whitfield, A. R. Porcari, C. Alvey, R. Abel, W. Bullen and D. Hartman, Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin,(2011) 378-388; DOI: 10.1177/0091270010366446.
    Open DOISearch in Google Scholar
  119. 119. J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman and P. J. Neuvonen, Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes,(2002) 1352-1356.
    Open DOISearch in Google Scholar
  120. 120. X. Wen, J. S. Wang, J. T. Backman, K. T. Kivistö and P. J. Neuvonen, Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9,.(2001) 1359-1361.
    Search in Google Scholar
  121. 121. H. Fujino, I. Yamada, S. Shimada, M. Hirano, Y. Tsunenari and J. Kojima, Interaction between fibrates and statins - metabolic interactions with gemfibrozil,(2003) 161-176.
    Open DOISearch in Google Scholar
  122. 122. J. T. Backman, C. Kyrklund, K. T. Kivistö, J. S. Wang and P. J. Neuvonen, Plasma concentrations of active simvastatin acid are increased by gemfibrozil,(2000) 122-129.
    Open DOISearch in Google Scholar
  123. 123. T. C. Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams and C. M. Loi, Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid,(2007) 1315-1324.
    Open DOISearch in Google Scholar
  124. 124. C. Kyrklund, J. T. Backman, K. T. Kivistö, M. Neuvonen, J. Laitila and P. J. Neuvonen, Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate,(2001) 340-345.
    Open DOISearch in Google Scholar
  125. 125. C. Kyrklund, J. T. Backman, M. Neuvonen and P. J. Neuvonen, Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance,(2003) 538-544.
    Open DOISearch in Google Scholar
  126. 126. P. Mathew, T. Cuddy, W. G. Tracewell and D. Salazar, An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers,(2004) 33.
    Search in Google Scholar
  127. 127. J. D. Spence, C. E. Munoz, L. Hendricks, L. Latchinian and H. E. Khouri, Pharmacokinetics of the combination of fluvastatin and gemfibrozil,(1995) 80A-83A.
    Search in Google Scholar
  128. 128. N. Bizzaro, E. Bagolin, L. Milani, C. Cereser and B. Finco, Massive rhabdomyolysis and simvastatin,(1992) 1504.
    Search in Google Scholar
  129. 129. R. A. Boyd, R. H. Stern, B. H. Stewart, X. Wu, E. L. Reyner, E. A. Zegarac, E. J. Randinitis and L. Whitfield, Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion,(2000) 91-98.
    Open DOISearch in Google Scholar
  130. 130. C. M. Ballantyne, A. Corsini, M. H. Davidson, H. Holdaas, T. A. Jacobson, E. Leitersdorf, W. März, J. P. Reckless and E. A. Stein, Risk for myopathy with statin therapy in high-risk patients,(2003) 553-564.
    Open DOISearch in Google Scholar
  131. 131. P. D. Thompson, P. Clarkson and R. H. Karas, Statin-associated myopathy,(2003) 1681-1690.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/acph-2013-0022 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 277 - 293
Published on: Oct 22, 2013
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Keywords:
statins,
drug interactions,
cytochrome P450 (CYP) enzymes,
drug transporters,
adverse effects
Related subjects:
Pharmacy,
Pharmacy, other

© 2013 Anida Causevic-Ramosevac, Sabina Semiz, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 63 (2013): Issue 3 (September 2013)
Next article